MHRA to discuss innovation in Controlled Release and Combination Products

LONDON - Jan. 4, 2016 - PRLog -- SMi’s 13th annual Controlled Release conference will enable you to engage you in discussions with industry leaders to discover the latest innovations, as well as guiding you through the latest regulatory updates to ensure strict compliance. The two-day programme will also address up-and-coming novel controlled release strategies to accelerate commercialisation with case studies from GSK, Merck, UCB Pharma, Astra Zeneca, Critical Pharmaceuticals, Novo Nordisk, Lundbeck, Diurnal, Ipsen, MedImmune, MHRA and more.

Furthermore, SMi is delighted to announce that the MHRA's Pharmaceutical Assessor, Marion Westwood, will be delivering an opening address on Day One titled, 'Supporting innovation in controlled release and combination products'. Key points covered include:
• Discuss the latest innovations surrounding controlled release
• Gain key regulatory updates from leading competent authorities talking specifically on grey areas such as the regulatory environment surrounding combination products
• Case study on work with OxSonics

Speaker Panel includes:
• David Elder, Due Diligence Director, GlaxoSmithKline
• Andy Lewis, Director Novel Drug Delivery Technologies, Ipsen
• Sachin Mittal, Senior Principal Scientist, Merck
• Marianne Ashford, Principal Scientist Drug Targeting, AstraZeneca
• Sune Andersen, Principal Scientist, Novo Nordisk

To view the full speaker line-up and conference programme, visit http://www.smi-online.co.uk/2016controlledrelease4.asp

Plus, don't miss two interactive post-conference workshops taking place on 20th April 2016:

A: QbD/PAT Driven Controlled Release Design and Development | Led by Cristiana Campa, Head, Quality by Design Integration, GlaxoSmithKline and Jerome Mantanus, Senior Scientist QbD/PAT Drug Product Formulation, UCB Pharma

B: Exploring Controlled Release Drug Delivery Methods | Led by Rene Holm, Senior Director, Lundbeck; Clive Wilson, Professor of Pharmaceutics, University of Strathclyde; Ijeoma Uchegbu, Scientific Secretary CRS, Chair in Pharmaceutical Nanoscience, University Of London and CEO, Nanometrics